Analysts expect that Myomo, Inc. (NASDAQ:MYO) will post ($0.17) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Myomo’s earnings, with estimates ranging from ($0.17) to ($0.16). Myomo reported earnings per share of ($0.22) during the same quarter last year, which suggests a positive year over year growth rate of 22.7%. The company is scheduled to issue its next earnings results on Thursday, March 5th.
On average, analysts expect that Myomo will report full year earnings of ($0.67) per share for the current financial year, with EPS estimates ranging from ($0.69) to ($0.64). For the next financial year, analysts expect that the business will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.67) to ($0.25). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Myomo.
Myomo (NASDAQ:MYO) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.16). The business had revenue of $0.61 million during the quarter, compared to the consensus estimate of $1.30 million.
Shares of MYO remained flat at $$0.50 during trading hours on Tuesday. The stock had a trading volume of 6,514 shares, compared to its average volume of 131,900. Myomo has a 12-month low of $0.43 and a 12-month high of $1.90. The firm’s 50 day simple moving average is $0.59 and its 200 day simple moving average is $0.73.
Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.
Read More: What are Institutional Investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.